1037P - Economic burden of cancer associated thrombosis in Germany

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Bioethics, Legal, and Economic Issues
Presenter Rainer Lipp
Citation Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377
Authors R. Lipp1, M. Feuerbach1, F. Freigang1, N. Schmidt2, E. Reimer3
  • 1Rwe Research, GermanOncology GmbH, 20457 - Hamburg/DE
  • 2Rwes, IMS Health, 60598 - Frankfurt am Main/DE
  • 3Patient Access Thrombosis, Leo Pharma A/S, Copenhagen/DK



The risk of developing a Venous Thromboembolism (VTE) is especially high in cancer patients. Despite thrombosis being a relatively common co-morbidity in several types of cancers, there are only a few studies on the ecomonic burden of cancer-associated thrombosis (CAT) worldwide. The aim of this study was to analyse the patients with most common types of cancer who experience a CAT, and to calculate the associated total health utilization costs in Germany.


Patient's data (e.g. anticancer medication, hospitalisations, oncological services etc.) were sampled under real-world conditions in 26 German oncological practices by reviewing and evaluating every medical record from each patient. In the analysis n = 2.361 patients with colorectal (CRC – 21%), breast (BC – 42%), lung (LC – 21%) and prostate cancer (PC – 16%) who received at least one systemic antitumor treatment in 2014-2015 were included. The total health utilization and costs were calculated for different patient groups (all patients vs. patients with CAT vs. patients without CAT) and for cancer types. Therefore, all treatments and procedures in the database were transferred into German reimbursement systems for health care services.


2,361 cancer patients were included in the analysis with a mean follow-up duration of 41 months. n = 407 patients (17%) developed a CAT and were treated with antithrombotic medication. In total n = 407 hospitalizations (9.8% due to VTE) with a mean length of 10 days (8 days with a cause of VTE) were found. The annual health utilization costs per patient were in mean 16,199 €. The distribution of costs were: 20% for hospitalizations, 11% for medical CAT therapies and 69% for non-CAT related services or medications. 17% of patients with CRC, BC, LC and PC developed a CAT during an anticancer treatment. 59% of these patients were hospitalized with a total length of 17 days over a mean of 1.7 inpatient stays during the 41 months.


The economic burden of CAT is substantial, as the majority of CAT patients were hospitalized for a longer period of time. However, costs for CAT therapies (including medication and inpatient CAT therapy) were only 11% of the total costs in patients during the period in which patients were receiving anticancer therapy.

Clinical trial identification

Legal entity responsible for the study

GermanOncology GmbH


LEO Pharma


R. Lipp, M. Feuerbach, F. Freigang, N. Schmidt: Research support by LEO Pharma. E. Reimer: Employed by LEO Pharma.